#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Vildagliptin: experience and prospects


Authors: Alena Šmahelová
Authors‘ workplace: III. interní gerontometabolická klinika LF UK v Hradci Králové a FN Hradec Králové
Published in: Forum Diab 2018; 7(1): 76-79
Category:

Overview

Vildagliptin is one of the modern antidiabetic drugs from the incretin group. It is a dipeptidyl peptidase-4 (DPP-4i) inhibitor, whose effectiveness and safety (including cardiovascular) have been proven in a number of preclinical, randomized clinical and large-scale international observation studies in clinical practice. These effects have also been verified in elderly patients with type 2 diabetes and in patients with type 2 diabetes a renal impairment. Currently its effect on patients in early stages of diabetes is being tested, which is essential for further course of dia­betes with the development of late complications.

Key words:
actual clinical practice, clinical studies, complications of diabetes, effectiveness, safety, vildagliptin

Received:
17. 2. 2018

Accepted:
5. 3. 2018


Sources

1. Marfella R, Barbieri M, Grella R et al. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications 2010; 24(2): 79–83. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jdiacomp.2009.01.004>.

2. Rizzo MR, Barbieri M, Marfella R et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012; 35(10): 2076–2082. Dostupné z DOI: <http://dx.doi.org/10.2337/dc12–0199>. Erratum in Diabetes Care 2014; 37(2): 587.

3. Barbieri M, Rizzo MR, Marfella R et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis 2013; 227(2): 349–354. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2012.12.018>.

4. Alagiakrishnan K, Sankaralingam S, Ghosh M et al. Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer‘s disease. Discov Med 2013; 16(90): 277–286.

5. Ma QH, Jiang LF, Mao JL et al. Vildagliptin prevents cognitive deficits and neuronal apoptosis in a rat model of Alzheimer‘s disease. Mol Med Rep 2018; 17(3): 4113–4119. Dostupné z DOI: <http://dx.doi.org/10.3892/mmr.2017.8289>.

6. Blüher M, Schweizer A, Bader G et al. Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes. Vasc Health Risk Manag 2014; 10: 661–664. Dostupné z DOI: <http://dx.doi.org/10.2147/VHRM.S73608>.

7. International Diabetes Federation. Managing Older People with Type 2 Diabetes: Global Guideline. International Diabetes Federation: 2013. ISBN 2–930229–86–1. Dostupné z WWW: .

8. Konrat C, Boutron I, Trinquart L et al. Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. PLoS One 2012;7:e33559. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0033559>.

9. Strain WD, Agarwal AS, Paldanius PM. Individualizing treatment targets for elderly patients with type 2 diabetes: factors influencing clinical decision making in the 24-week, randomized INTERVAL study. Aging (Albany NY) 2017; 9(3): 769–777. Dostupné z DOI: <http://dx.doi.org/10.18632/aging.101188>.

10. Parving HH, Lewis JB, Ravid M et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective. Kidney Int 2006, 69(11): 2057–2063. Dostupné z DOI: <http://dx.doi.org/10.1038/sj.ki.5000377>.

11. He YL, Kulmatycki K, Zhang Y et al. Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment. Int J Clin Pharmacol Ther 2013; 51(9):693–703. Dostupné z DOI: <http://dx.doi.org/10.5414/CP201885>.

12. Kothny W, Shao Q, Groop PH et al. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab 2012; 14(11): 1032–1039. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1463–1326.2012.01634.x>.

13. Groop PH, Cooper ME, Perkovic V et al. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 2013; 36(11): 3460–3468. Dostupné z DOI: <http://dx.doi.org/10.2337/dc13–0323>.

14. Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369(14): 1317–1326. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1307684>.

15. Monami M, Ahren B, Dicembrini I et al. Dipeptidylpeptidase-4 inhibitors and cardiovascular risk: a metaanalysis of randomized clinical trials. Diabetes Obes Metab 2013; 15(2): 112–120. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12000>.

16. Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375(4): 311–322. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1603827>.

17. Mathieu C, Barnett AH, Brath H et al., Effectiveness andtolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract 2013;67(10): 947–956. Dostupné z DOI: <http://dx.doi.org/10.1111/ijcp.12252>.

18. VERIFY: A study to compare combination regimen with vildagliptin & metformin versus metformin in treatment-naďve patients with type 2 diabetes mellitus. ClinicalTrials.gov Identifier: NCT01528254. Dostupné z WWW: <https://clinicaltrials.gov/ct2/show/NCT01528254>.

19. [World Health Organization (WHO)]. Prevention of Blindness from Diabetes Mellitus 2017. WHO: 2017. ISBN 9789241547123. Dostupné z WWW: <http://www.who.int/blindness/en/>.

20. [World Health Organization (WHO)]. Diabetes Fact Sheet. 2018. Dostupné z WWW: <http://www.who.int/mediacentre>.

21. Liebl A, Mata M, Eschwège E. [ODE-2 Advisory Board]. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia 2002; 45(7 Suppl 1): S23–28.

22. de Pablos-Velasco P; Bradley P, Eschwège E et al. The PANORAMA pan-European survey: glycaemic control and treatment patterns in patients with type 2 diabetes. Diabetologia 2010; 53(Suppl 1): Abstract 1012.

23. Ali MK, Bullard KM, Saaddine JB et al. Achievement of goals in U.S. diabetes care, 1999–2010. N Engl J Med 2013; 368(17): 1613–1624. Dostupné z DOI: <http://doi: 10.1056/NEJMsa1213829>. Erratum in N Engl J Med. 2013; 369(6): 587.

24. de Pablos-Velasco P, Parhofer KG, Bradley C et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol (Oxf) 2014; 80(1): 47–56. Dostupné z DOI: <http://dx.doi.org/10.1111/cen.12119>.

25. Viberti G, Kahn SE, Greene DA et al. A Diabetes Outcome Progression Trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25(10): 1737–1743.

26. Patel A, MacMahon S, Chalmers J et al. [The ADVANCE Collaborative Group]. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2008; 358(24): 2560–2572. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0802987>.

27. Williamson DF, Thompson TJ, Thun M et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23(10): 1499–1504.

28. Ten Years of Vildagliptin. European Endocrinology 2017; 13(2): 54–72.

Labels
Diabetology Endocrinology Internal medicine
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#